Private Advisory Group LLC Purchases 16,426 Shares of Axon Enterprise, Inc $AXON

Private Advisory Group LLC purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,426 shares of the biotechnology company’s stock, valued at approximately $6,940,000.

A number of other large investors have also modified their holdings of the stock. Keel Point LLC increased its holdings in Axon Enterprise by 4.4% during the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 25 shares during the period. Bridgewater Advisors Inc. raised its position in Axon Enterprise by 4.4% in the 2nd quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 26 shares in the last quarter. Pinnacle Wealth Planning Services Inc. lifted its stake in Axon Enterprise by 7.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 361 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 26 shares during the last quarter. 44 Wealth Management LLC raised its holdings in shares of Axon Enterprise by 6.0% in the 1st quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 30 shares in the last quarter. Finally, Owl Creek Wealth Partners LLC raised its holdings in shares of Axon Enterprise by 84.8% in the 2nd quarter. Owl Creek Wealth Partners LLC now owns 85 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Down 2.6%

Shares of Axon Enterprise stock opened at $307.11 on Friday. Axon Enterprise, Inc has a 1 year low of $291.45 and a 1 year high of $665.07. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.60 and a current ratio of 3.00. The company has a market capitalization of $25.01 billion, a P/E ratio of 98.43, a PEG ratio of 5.99 and a beta of 1.48. The company’s fifty day moving average is $422.24 and its two-hundred day moving average is $469.16.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). Axon Enterprise had a net margin of 7.56% and a return on equity of 3.87%. The business had revenue of $908.55 million during the quarter, compared to analyst estimates of $934.33 million. During the same quarter in the prior year, the firm posted $1.17 earnings per share. The company’s revenue for the quarter was up 27.8% compared to the same quarter last year. Analysts forecast that Axon Enterprise, Inc will post 2.10 earnings per share for the current year.

Top Axon Enterprise Stories

Investors following AXON have been watching these stories:

• Positive Sentiment: Maryland’s Howard County Police Department adopted Axon’s drone-as-first-responder solutions, including Skydio X10 drones, counter-drone technology and AI tools. The deployment supports Axon’s public-safety technology demand, though no contract value was disclosed. Article: Axon Air Drone as First Responder Program Soars into Howard County, Maryland
• Negative Sentiment: Axon’s third-quarter adjusted EPS was reported below consensus, and revenue of $908.55 million also trailed estimates of $934.33 million. Revenue nevertheless grew 27.8% year over year. The earnings shortfall is a key reason for the shares’ recent weakness; Barclays has also lowered its expectations for the stock. Article: Levi & Korsinsky Investigation Notice Article: Barclays Lowers Expectations for Axon
• Negative Sentiment: Two law firms publicized investigations into potential securities-law claims related to Axon’s earnings report. These are allegations under investigation, not findings of wrongdoing, but add legal uncertainty and could keep investor attention on the earnings miss. Article: SBS Law Fraud Investigation Notice

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the sale, the president directly owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of Axon Enterprise stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the completion of the transaction, the insider owned 97,761 shares in the company, valued at $61,266,818.70. This trade represents a 8.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,397 shares of company stock valued at $21,234,034 in the last quarter. 4.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Barclays lowered their target price on shares of Axon Enterprise from $688.00 to $507.00 and set an “overweight” rating for the company in a research note on Monday. TD Cowen lowered their price objective on Axon Enterprise from $825.00 to $800.00 and set a “buy” rating for the company in a research report on Monday, October 26th. The Goldman Sachs Group dropped their price objective on Axon Enterprise from $715.00 to $675.00 and set a “buy” rating on the stock in a report on Monday, September 21st. UBS Group increased their price objective on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. cut their target price on Axon Enterprise from $755.00 to $610.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average price target of $612.18.

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.